Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Intellia Therapeutics, Inc. NTLA

Healthcare  —  Biotechnology
11.75 (0.41) (3.37%) as of 25 Sep
Market cap
$1.7B
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Intellia Therapeutics, Inc. (NTLA) Business Profile

Updated before January 2025

Company Overview

Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a leading biotechnology company specializing in the development of innovative genome-editing technologies. Founded in 2014, the company is headquartered in Cambridge, Massachusetts, USA. Intellia was co-founded by Jennifer Doudna, a Nobel Prize-winning scientist recognized for her pioneering work in CRISPR-Cas9 gene-editing technology. The company’s mission is to harness the power of CRISPR-based therapies to treat and potentially cure genetic diseases.

Intellia’s leadership team includes John Leonard, M.D., who serves as the President and Chief Executive Officer. Dr. Leonard brings decades of experience in drug development and biotechnology. Other key executives include Glenn Goddard, the Chief Financial Officer, and Laura Sepp-Lorenzino, Ph.D., the Chief Scientific Officer. Together, the leadership team drives Intellia’s strategic vision and operational excellence.

Core Business Segments

Intellia Therapeutics operates primarily in the field of genome editing, focusing on two major business segments:

1. In Vivo Programs

Intellia’s in vivo programs aim to develop therapies that directly edit genes within the human body. These therapies are designed to address genetic diseases by targeting specific cells and tissues. Key products and programs under this segment include:

  • NTLA-2001: A CRISPR-based therapy for the treatment of transthyretin amyloidosis (ATTR), a rare and life-threatening disease caused by misfolded transthyretin proteins.
  • NTLA-2002: A therapy targeting hereditary angioedema (HAE), a genetic disorder characterized by recurrent episodes of severe swelling.
  • NTLA-3001: A preclinical program targeting alpha-1 antitrypsin deficiency (AATD), a genetic disorder that can lead to liver and lung disease.

2. Ex Vivo Programs

Ex vivo programs involve editing cells outside the body and then reintroducing them to the patient. These therapies are primarily focused on oncology and immunology. Key initiatives include:

  • Allogeneic Cell Therapies: Developing off-the-shelf immune cell therapies for cancer treatment.
  • Hematopoietic Stem Cell (HSC) Programs: Targeting genetic blood disorders such as sickle cell disease and beta-thalassemia.

Business Model

Intellia Therapeutics operates on a research-driven business model that integrates cutting-edge science with strategic partnerships. The company generates revenue through:

  • Collaborations and Licensing Agreements: Intellia has established partnerships with leading pharmaceutical companies, including Regeneron Pharmaceuticals, to co-develop and commercialize CRISPR-based therapies.
  • Milestone Payments and Royalties: The company earns milestone payments and royalties from its partners as its therapies progress through clinical trials and reach commercialization.
  • Research and Development (R&D) Funding: Intellia invests heavily in R&D to advance its pipeline of therapies and maintain its leadership in the genome-editing space.

Strategic Direction

Intellia Therapeutics is focused on expanding its pipeline of CRISPR-based therapies and advancing its clinical programs. Key strategic priorities include:

  • Clinical Development: Progressing NTLA-2001 and NTLA-2002 through clinical trials and seeking regulatory approvals.
  • Pipeline Expansion: Developing new therapies for additional genetic diseases and exploring novel applications of CRISPR technology.
  • Global Reach: Expanding its presence in international markets to address unmet medical needs worldwide.
  • Sustainability Goals: Committing to ethical and sustainable practices in the development and commercialization of its therapies.

Competitive Landscape

Intellia Therapeutics operates in a highly competitive biotechnology sector, with key competitors including:

  • CRISPR Therapeutics: A leading company in the development of CRISPR-based therapies, focusing on genetic diseases and oncology.
  • Editas Medicine: Another major player in the genome-editing space, with a focus on both in vivo and ex vivo therapies.
  • Beam Therapeutics: Specializing in base editing, a next-generation genome-editing technology.
  • Sangamo Therapeutics: A biotechnology company developing gene-editing therapies using zinc finger nucleases (ZFNs).

Risk Factors

Intellia Therapeutics faces several risks that could impact its business operations and financial performance:

  • Regulatory Challenges: The approval process for gene-editing therapies is complex and subject to stringent regulatory scrutiny.
  • Market Dependence: The company’s success is heavily reliant on the commercialization of its lead programs, NTLA-2001 and NTLA-2002.
  • Supply Chain Disruptions: Dependence on specialized materials and manufacturing processes poses a risk of supply chain interruptions.
  • Competition: Intense competition in the biotechnology sector could impact Intellia’s market share and pricing power.
  • Ethical Concerns: Public and regulatory concerns about the ethical implications of genome editing could affect the adoption of Intellia’s therapies.

Recent Developments

Intellia Therapeutics has made significant progress in advancing its pipeline and corporate strategy:

  • Clinical Milestones: The company recently announced positive interim data from its Phase 1 clinical trials for NTLA-2001 and NTLA-2002, demonstrating safety and efficacy.
  • Partnership Expansion: Intellia expanded its collaboration with Regeneron Pharmaceuticals to include additional targets and indications.
  • Technological Innovations: The company continues to enhance its CRISPR platform to improve precision, efficiency, and scalability.
  • Global Developments: Intellia is actively engaging with regulatory agencies in multiple regions to facilitate the global development of its therapies.

Investment Considerations

Investors considering Intellia Therapeutics should weigh the following strengths and risks:

Strengths

  • Pioneering Technology: Intellia is at the forefront of CRISPR-based genome editing, with a robust pipeline of innovative therapies.
  • Strong Partnerships: Collaborations with industry leaders like Regeneron provide financial support and strategic expertise.
  • Clinical Progress: Positive clinical data for NTLA-2001 and NTLA-2002 validate the company’s approach and increase the likelihood of regulatory approval.

Risks

  • Early-Stage Company: Intellia is still in the clinical development phase, with no approved products on the market.
  • High R&D Costs: The company’s heavy investment in R&D could impact its financial performance in the short term.
  • Regulatory and Ethical Challenges: The nascent field of genome editing faces significant regulatory and ethical hurdles.

Conclusion

Intellia Therapeutics is a trailblazer in the field of genome editing, leveraging CRISPR technology to develop transformative therapies for genetic diseases. With a strong pipeline, strategic partnerships, and a commitment to innovation, the company is well-positioned for long-term growth. However, investors should carefully consider the risks associated with early-stage biotechnology companies. As Intellia advances its clinical programs and expands its global footprint, it has the potential to revolutionize the treatment of genetic disorders and solidify its position as a leader in the biotechnology industry.